SuperworthEnliven Therapeutics market cap ELVN
Share price times shares outstanding: what the whole company sells for, since 2020.
- Today, Oct 23, 2026
- $3B
- Highest close in our data
- $4.4B
- Aug 2026
Enliven Therapeutics is worth $3B at the close on Oct 23, 2026, at $41.52 a share.
That is up 149% over the last year and up 3120% over five years.
Its highest close in our data was $4.4B in Aug 2026.
Market cap over time
Year by year
| Year | End of year | Low | High | Change |
|---|---|---|---|---|
| 2026 so far | $3B | $922.3M | $4.4B | +214% |
| 2025 | $967.4M | $804.7M | $1.4B | −11% |
| 2024 | $1.1B | $494.9M | $1.4B | +92% |
| 2023 | $570.4M | $107.3M | $888.9M | +431% |
| 2022 | $107.5M | $27.1M | $129.9M | +82% |
| 2021 | $59.1M | $59.1M | $245.4M | −85% |
| 2020 | $383.8M | $273.9M | $814.3M | n/a |
Against its peers
Companies in Drug Manufacturers - General nearest Enliven Therapeutics' size, closest first, today.
| Company | Market cap |
|---|---|
| ELVNEnliven Therapeutics | $3B |
| NRIXNurix Therapeutics | $2.8B |
| OGNOrganon | $3.6B |
| LQDALiquidia | $3.8B |
| ARQTArcutis Biotherapeutics | $3.9B |
| INDVIndivior Pharmaceuticals | $4.1B |
| PBHPrestige Consumer Healthcare | $2.3B |
| HRMYHarmony Biosciences | $2.1B |
| ANIPANI Pharmaceuticals | $1.7B |
| PAHCPhibro Animal Health | $1.6B |
| KNSAKiniksa Pharmaceuticals International | $6B |
| Peer median | $3.2B |
What the market cap tells you
Share price times shares outstanding: what the whole company sells for today.
Size, not quality. Large caps move slower and are covered more. That is all it tells you.
More on Enliven Therapeutics
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.